Table 5.
Bleeding events WHO grade 2 or more reported during the study.
| Bleeding While on Eltrombopag Treatment | Value |
|---|---|
| Patients, n/N (%) | 3/38 * (7.9) |
| WHO grade | 3.0 (3.0, 4.0) |
| Fatal, n/N (%) | 0/3 (0) |
| Location, n/N (%) | |
| Several † | 1/3 (33.3) |
| Subdural | 1/3 (33.3) |
| Nasopharynx | 1/3 (33.3) |
| Features of patients who had a bleeding episode | |
| Platelet count before the start of eltrombopag | 18.5 (20.0, 27.0) |
| Time from platelet count < 20 × 109/L to start of eltrombopag, days | 32 (18, 75) |
| Time on eltrombopag treatment when bleeding occurred, days | 16 (15, 70) |
Results are median (IQR), except otherwise indicated. * Another patient had a non-fatal grade 4 brain hemorrhage 5.5 weeks after platelet count < 20 × 109/L was detected and 2.5 weeks before eltrombopag was started. † Mucosal and digestive bleeding and petechiae. IQR, interquartile range; PLT, platelets; TCP, thrombocytopenia; WHO, World Health Organization.